Skip to main content
Premium Trial:

Request an Annual Quote

Kenneth Berlin

Rosetta Genomics President and CEO Kenneth Berlin is resigning from the company effective April 18 to pursue other opportunities. He will assist the company in a smooth transition with ongoing projects, the company said. Berlin joined Rosetta Genomics in November 2009 as president and CEO. Before that, he was worldwide general manager at Veridex, a Johnson & Johnson company. He joined J&J in 1994 and was its corporate counsel for six years, according to Rosetta Genomics' website. From 2001 to 2004, he was vice president of licensing and new business development in the pharmaceutical group at J&J, and from 2004 to 2007, he was worldwide VP of franchise development at Ortho Clinical Diagnostics, also a J&J company. 

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.